Below is a list of our clients attending JP Morgan this year. Please email us at
JPM-meetings@bplifescience.com or call (415) 375-3340 Ext. 4 with any meeting requests.

JP Morgan 2016 Blueprint Client Profiles

Accelerate Diagnostics (NASDAQ: AXDX) - In vitro diagnostics company focused on the ultrafast identification and antibiotic susceptibility profiling of infectious respiratory and blood-borne pathogens.

Profile: Accelerate’s ID/AST technology platform is a proprietary culture-free, 5 hour process that uses genomic and phenotypic screening of pathogens to significantly decrease the time necessary to identify and determine the antibiotic susceptibility of an infection with high sensitivity and specificity. Company was recently granted CE Mark for the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. Currently in FDA clinical stage trials for the Accelerate ID/AST System and the ID/AST Blood Culture Assay.

Market Cap: 745M (as of Nov 18, 2015)
Cash: $48M (at June 30, 2015)

Achaogen (NASDAQ: AKAO) - Developing best-in-class and first-in-class antibacterials for the treatment of multi-drug resistant gram-negative bacteria. Lead product plazomicin in two pivotal Phase 3 studies: CARE and EPIC. The EPIC study is for patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP) caused by gram-negative bacteria while CARE is a controlled study for the treatment of patients with bloodstream infections (BSI) and pneumonia due to carbapenem-resistant Enterobacteriaceae (CRE).

Profile: In September 2014, the company began patient enrollment in CARE’s pivotal study which is being conducted under a Special Protocol Assessment agreement with the FDA, and is funded in part with a contract from the Biomedical Advanced Research and Development Authority (BARDA). Recently, AKAO announced “Amendment II” to this ongoing study which aims to generate data in a broader range of CRE patients and expedite plazomicin’s path to market by increasing enrollment. The Company was awarded a $60M contract option by BARDA to fund the trial through to registration (full BARDA contract totals $104M). Additionally, Achaogen is developing a robust pipeline in the gram-negative space, led by LpxC inhibitors and antibacterial antibodies in preclinical development targeted MDR pseudomonas.

Market Cap: 105M (as of Nov 18, 2015)
Cash: 70M (at Sept 30, 2015)

Upcoming Milestones

• Q4 2015 - Initiate pivotal EPIC trial in cUTI
• Q2 2016 - All planned CARE Amendment 2 sites active
• H1 2016 - Nomination of development candidate LpxC Inhibitor
• H2 2016 - Therapeutic antibody - lead candidate identification
• 2016 - Potential exercise of Option 3 BARDA funding
• H2 2017 - EPIC top-line results and NDA submission
• H1 2018 - Launch of Plazomicin for cUTI and AP
• H2 2018 - Supplemental NDA submission for Plazomicin for BSI and pneumonia (CARE)

Cerus Corporation (NASDAQ: CERS) - Commercial stage biomedical products company focused on blood safety and a global leader in blood pathogen inactivation. Marketing the INTERCEPT Blood system in the U.S. and abroad for platelets and plasma which is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood.

Profile: INTERCEPT blood system is FDA approved for INTERCEPT plasma and platelets, and commercialized in over 100 centers in the United States, EU, the Middle East, and select countries in other areas of the world. Primary endpoints successfully met for EU Phase III and US Phase II red blood cell studies. Potential 2017 CE Mark approval for INTERCEPT red cells. Recently appointed new Chief Medical Officer Richard Benjamin, MD former CMO of American Red Cross.

Market Cap: $504M (as of Nov 18, 2015)
Cash: $107M (at Sept 30, 2015)
2015 Revenues: 24.6M (at Sept 30, 2015)

Upcoming Milestones

• Q4 2015 - Initiate Phase IV PIPER study
• Q4 2015 - Final Draft of FDA Bacterial Safety Guidance
• Q1 2016 - Approval Decision for Platelets in 100% Plasma

Nexvet (NASDAQ: NVET) - A veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing novel, species-specific biologics.

Profile: Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (“mAbs”) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost. In November 2015, lead program (NV-01) achieved positive results from its pivotal study in dogs with osteoarthritis which will form the basis for US and EU marketing approvals of the first ever mAb for companion animals. Additionally, in June 2015, Nexvet reported positive top-line results from a proof-of-concept (POC) efficacy study and a high-dose safety study, for NV-02, a species-specific mAb targeting osteoarthritic pain in cats. The Ireland based company operates globally and has a strong financial position ($55.5m in cash) resulting from its recently completed US IPO (February 2015). Nexvet also recently signed a collaboration and distribution agreement with Virbac (outside U.S. and Canada).

Market Cap: $28M (as of Nov 18, 2015)
Cash: $47.7M (at Sept. 30, 2015)

Upcoming Milestones

• Q1 2016 - Completion of additional pilot studies for NV-01 in OA and PoC studies in pruritis
• Q1 2016 - Completion of POC study for NV-08 (anti-TNF)
• Q2 2016 - Receipt of Pilot study results for NV-02 in feline pain
• Q2 2016 - Submission of efficacy section for NV-01
• Q2 2016 - New Irish clinical and commercial manufacturing facility operational
• 2016 - Protocol finalization for NV-02 and commencement of Pivotal study
• 2016 - Multiple products entering and completing PoC studies
• 2016 - Preparation for 2017 USDA filings for conditional approvals – path to commercialization

Prolacta Bioscience (Private) - Commercial stage developer of human milk-based neonatal nutritional products that meet the needs of critically ill, premature infants in the NICU. Commenced commercialization in the US in 2009 and the company has been cash flow positive since 2011. Net revenues for 2015 are projected to be $56 million (+25% y/y). Exploring 2016 IPO to accelerate commercial geographic expansion in EU and invest in a broader therapeutic R & D pipeline.

Profile: Company pioneered the development of human milk-based neonatal nutritional products and is building a broad therapeutic pipeline by leveraging plasma expertise. Lead product, Prolact+ Fortifier, is the market leader in the US with 10% –15% current market share of a growing of $382 –$573 million US market opportunity. The Company truly leads the industry in the quality and safety of nutritional products made from breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk.

Upcoming Milestones

• Human milk based products being evaluated for additional neonatal and pediatric indications (Infant Cardiac and Pediatric BMT products)
• Human milk fractionated biologics in R&D (e.g. Human Milk Oligosaccharides {HMO})
• Canadian Clinical Prolact+Trial (124 babies primary outcome feeding intolerance and growth). Enrollment completion anticipated in 2015.

SuperSonic Imagine (Euronext: SSI, FR0010526814)- Commercial stage company specializing in ultrasound medical imaging with application versatility across radiology, urology, hepatology, vascular & OB/Gyn. Marketing Aixplorer™, a next generation multi-dimensional ultrasound imaging platform that offers not just superior image quality but also an accurate assessment of tissue elasticity providing superior diagnostic precision. €21.6m revenues in 2014=27% year-over-year growth. Revenue from China up +124% in 1H2015 vs 1H2014.

Profile: Founded in 2005 by Jacques Souquet (founded SonoSite, sold to Fuji Film in 2012 for 995M$), Aixplorer™ leverages ShearWave™ Elastography, a technology that enables physicians to visualize and analyze the stiffness of tissue. Its built-in UltraFastTM software platform has the ability to acquire images 200 times faster than conventional ultrasound. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets, including CE mark (Feb 09) and FDA 510 K (Aug 09). The company’s commercialization strategy includes its robust internal sales force and market exclusive distribution agreements such as Konica Minolta in Japan.

Upcoming Milestones

• Reinvigorate US sales of the Aixplorer by launching dedicated SSI sales team and deprioritizing third-party sales
• Leverage Aixplorer’s technological potential with emphasis on cost reduction equipment
 such as mobile/compact version and shared services
• Continue to extend applications in addressable markets such as urology, obstetrics, screening & therapy and trans cranial Doppler
• Explore product acquisitions to optimize in-house sales force